Authors
Loading...
Randomized trial evaluates migraine prevention outcomes in adults using anti-CGRP monoclonal antibodies, suggesting improvements in treatment standards.
Caronna et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: